Interim safety update on COUGH-1, the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine
Hørsholm, Denmark, April 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the first group of volunteers in the clinical Phase I/II study, COUGH-1, have been satisfactorily administered with the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine. The clinical study runs as planned with no untoward safety signal in now 18 healthy volunteers.The clinical Phase I/II study, COUGH-1, is designed to assess the power of the cVLP technology in combination with ExpreS[2]-made SARS-CoV2 antigens to safely induce a strong